A Phase II Trial of Revlimid and 'On Demand' Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 28 Aug 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 10 Oct 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 04 Feb 2016 Planned End Date changed from 1 Oct 2015 to 1 May 2016, as reported by ClinicalTrials.gov.